{"id":40101,"date":"2026-10-21T10:17:50","date_gmt":"2026-10-21T08:17:50","guid":{"rendered":"https:\/\/ggba.swiss\/orbis-medicines-and-novo-nordisk-partner-in-a-deal-worth-up-to-usd-1-4-billion\/"},"modified":"2026-10-21T10:20:48","modified_gmt":"2026-10-21T08:20:48","slug":"orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/","title":{"rendered":"Orbis Medicines et Novo Nordisk s&rsquo;associent dans un accord pouvant atteindre USD 1,4 milliard"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.orbismedicines.com\/\">Orbis Medicines<\/a> a conclu avec <a href=\"https:\/\/www.novonordisk.com\/\">Novo Nordisk<\/a> un accord strat\u00e9gique de collaboration et de licence pour d\u00e9couvrir et d\u00e9velopper des macrocycles oraux de nouvelle g\u00e9n\u00e9ration contre les maladies cardiom\u00e9taboliques. Annonc\u00e9 le 17 septembre 2026, l&rsquo;accord peut atteindre USD 1,4 milliard, soit un paiement initial et d&rsquo;\u00e9ventuels paiements d&rsquo;\u00e9tape de d\u00e9veloppement et de commercialisation, assortis de redevances \u00e9chelonn\u00e9es sur les futures ventes de produits. Novo Nordisk r\u00e9alisera aussi un investissement strat\u00e9gique dans Orbis. Les montants du paiement initial, des redevances et de l&rsquo;investissement n&rsquo;ont pas \u00e9t\u00e9 divulgu\u00e9s, et les cibles n&rsquo;ont pas \u00e9t\u00e9 nomm\u00e9es.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Une plateforme pilot\u00e9e par l&rsquo;IA pour des alternatives orales aux injectables<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Orbis se concentre sur les macrocycles, qu&rsquo;elle appelle nCycles : des mol\u00e9cules \u00e0 biodisponibilit\u00e9 orale visant des cibles d\u00e9j\u00e0 valid\u00e9es par des m\u00e9dicaments biologiques injectables. Ils sont con\u00e7us avec sa plateforme nGen, qui combine IA g\u00e9n\u00e9rative, synth\u00e8se \u00e0 haut d\u00e9bit et moteur d&rsquo;optimisation multiparam\u00e9trique dans un \u00ab lab in a loop \u00bb. Selon l&rsquo;entreprise, nGen s&rsquo;appuie sur des biblioth\u00e8ques de recherche de touches de 100 milliards de compos\u00e9s et peut synth\u00e9tiser et analyser jusqu&rsquo;\u00e0 100&rsquo;000 macrocycles en quelques semaines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Morten Graugaard, CEO d&rsquo;Orbis Medicines, affirme que l&rsquo;avenir de la d\u00e9couverte de m\u00e9dicaments biologiques oraux \u00ab se situe \u00e0 l&rsquo;intersection de l&rsquo;IA \u00bb avec des jeux de donn\u00e9es propri\u00e9taires sur les macrocycles et une chimie automatis\u00e9e. Brian Vandahl, Senior Vice President, Therapeutics Discovery chez Novo Nordisk, estime que la collaboration pourrait \u00ab ouvrir de nouvelles options de traitement oral aux patients atteints de maladies cardiom\u00e9taboliques \u00bb.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Des racines scientifiques \u00e0 l&rsquo;EPFL<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">La science \u00e0 l&rsquo;origine d&rsquo;Orbis a \u00e9t\u00e9 d\u00e9velopp\u00e9e \u00e0 l&rsquo;<a href=\"https:\/\/www.epfl.ch\/fr\/\">EPFL<\/a> par le professeur Christian Heinis et Sevan Habeshian. <a href=\"https:\/\/novoholdings.com\/\">Novo Holdings<\/a> a officiellement fond\u00e9 la soci\u00e9t\u00e9 en 2021 et l&rsquo;a pr\u00e9sent\u00e9e au public en f\u00e9vrier 2024 avec un tour de seed de EUR 26 millions codirig\u00e9 avec <a href=\"https:\/\/www.forbion.com\/\">Forbion<\/a>. Une s\u00e9rie A de EUR 90 millions men\u00e9e par <a href=\"https:\/\/www.nea.com\/\">NEA<\/a> a suivi en janvier 2025, avec l&rsquo;arriv\u00e9e de Lilly Ventures, Cormorant et EIFO comme nouveaux investisseurs. Orbis a lev\u00e9 \u00e0 ce jour EUR 116 millions en capital-risque.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orbis Medicines, soci\u00e9t\u00e9 de d\u00e9couverte de m\u00e9dicaments active \u00e0 Lausanne et \u00e0 Copenhague, a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard pour d\u00e9velopper des macrocycles oraux contre les maladies cardiom\u00e9taboliques.<\/p>\n","protected":false},"author":6,"featured_media":40098,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1179,1148,1188,1142],"class_list":["post-40101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-artificial-intelligence-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orbis Medicines signe pour USD 1,4 milliard avec Novo Nordisk<\/title>\n<meta name=\"description\" content=\"Orbis Medicines a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orbis Medicines signe pour USD 1,4 milliard avec Novo Nordisk\" \/>\n<meta property=\"og:description\" content=\"Orbis Medicines a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T08:17:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-21T08:20:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Orbis Medicines et Novo Nordisk s&rsquo;associent dans un accord pouvant atteindre USD 1,4 milliard\",\"datePublished\":\"2026-10-21T08:17:50+00:00\",\"dateModified\":\"2026-10-21T08:20:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"keywords\":[\"Artificial Intelligence\",\"Financing\",\"Healthcare\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\",\"name\":\"Orbis Medicines signe pour USD 1,4 milliard avec Novo Nordisk\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"datePublished\":\"2026-10-21T08:17:50+00:00\",\"dateModified\":\"2026-10-21T08:20:48+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Orbis Medicines a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"Orbis Medicines d\u00e9veloppe des macrocycles oraux gr\u00e2ce \u00e0 sa plateforme nGen, pilot\u00e9e par l'IA.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orbis Medicines et Novo Nordisk s&#8217;associent dans un accord pouvant atteindre USD 1,4 milliard\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orbis Medicines signe pour USD 1,4 milliard avec Novo Nordisk","description":"Orbis Medicines a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/","og_locale":"fr_FR","og_type":"article","og_title":"Orbis Medicines signe pour USD 1,4 milliard avec Novo Nordisk","og_description":"Orbis Medicines a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard.","og_url":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-10-21T08:17:50+00:00","article_modified_time":"2026-10-21T08:20:48+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Orbis Medicines et Novo Nordisk s&rsquo;associent dans un accord pouvant atteindre USD 1,4 milliard","datePublished":"2026-10-21T08:17:50+00:00","dateModified":"2026-10-21T08:20:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/"},"wordCount":389,"image":{"@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","keywords":["Artificial Intelligence","Financing","Healthcare","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/","url":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/","name":"Orbis Medicines signe pour USD 1,4 milliard avec Novo Nordisk","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","datePublished":"2026-10-21T08:17:50+00:00","dateModified":"2026-10-21T08:20:48+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Orbis Medicines a conclu avec Novo Nordisk une collaboration multicibles pouvant atteindre USD 1,4 milliard.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/10\/Orbis-Medicines-1180x811-1.jpeg","width":1180,"height":811,"caption":"Orbis Medicines d\u00e9veloppe des macrocycles oraux gr\u00e2ce \u00e0 sa plateforme nGen, pilot\u00e9e par l'IA."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/orbis-medicines-et-novo-nordisk-sassocient-dans-un-accord-pouvant-atteindre-usd-14-milliard\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Orbis Medicines et Novo Nordisk s&#8217;associent dans un accord pouvant atteindre USD 1,4 milliard"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=40101"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40101\/revisions"}],"predecessor-version":[{"id":40103,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/40101\/revisions\/40103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/40098"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=40101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=40101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=40101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}